Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novo Nordisk
Pharma
Novo Nordisk applies for FDA approval of semaglutide obesity pill
Novo Nordisk has submitted for FDA approval of an oral version of Wegovy. It would be the world’s first oral GLP-1 obesity treatment.
Kevin Dunleavy
Apr 22, 2025 8:50am
Top 20 pharma companies by 2024 revenue
Apr 21, 2025 3:00am
BMO says Lilly is pulling ahead of Novo in obesity market battle
Apr 17, 2025 4:30pm
Novo charts $1B-plus Brazilian production expansion for GLP-1s
Apr 8, 2025 9:40am
Novo’s Wegovy, J&J’s Tremfya led March TV ad spending totals
Apr 7, 2025 11:21am
Lilly files lawsuit against spa for selling repackaged Zepbound
Apr 7, 2025 5:00am
